With this background, we analyzed a cohort of 168 AML patients consecutively allotransplanted in our Institution between December 2015 and January 2022, for whom at least one between BM-CD34+ chimerism or BM-WT1 level was available at 1 and 3 months after allo-SCT. This evidence concerns the gene CD34 and acute myeloid leukemia.